FY2025 Earnings Estimate for PRAX Issued By HC Wainwright

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Praxis Precision Medicines in a note issued to investors on Thursday, November 13th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($12.84) per share for the year, up from their previous forecast of ($14.63). HC Wainwright has a “Buy” rating and a $258.00 price target on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q4 2025 earnings at ($2.88) EPS, Q1 2026 earnings at ($2.89) EPS, Q2 2026 earnings at ($2.89) EPS, Q3 2026 earnings at ($3.01) EPS, Q4 2026 earnings at ($3.05) EPS, FY2026 earnings at ($11.84) EPS, FY2027 earnings at ($9.03) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $35.74 EPS.

Other research analysts also recently issued reports about the stock. Jones Trading started coverage on shares of Praxis Precision Medicines in a research report on Thursday, September 18th. They set a “buy” rating and a $83.00 target price on the stock. Jefferies Financial Group reissued a “buy” rating and set a $300.00 price target (up from $65.00) on shares of Praxis Precision Medicines in a research note on Thursday, October 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Praxis Precision Medicines in a report on Thursday, November 13th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $280.00 target price (up previously from $65.00) on shares of Praxis Precision Medicines in a report on Friday, October 17th. Finally, Guggenheim reissued a “buy” rating and issued a $540.00 price target on shares of Praxis Precision Medicines in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $242.36.

Praxis Precision Medicines Stock Down 6.8%

Shares of PRAX stock opened at $184.13 on Monday. The firm has a market cap of $4.60 billion, a price-to-earnings ratio of -14.27 and a beta of 2.80. Praxis Precision Medicines has a 12 month low of $26.70 and a 12 month high of $206.71. The stock has a 50-day moving average price of $112.99 and a 200 day moving average price of $69.17.

Praxis Precision Medicines (NASDAQ:PRAX) last released its earnings results on Wednesday, November 5th. The company reported ($3.36) EPS for the quarter, beating the consensus estimate of ($3.45) by $0.09.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. grew its holdings in shares of Praxis Precision Medicines by 13.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,974,585 shares of the company’s stock valued at $83,031,000 after buying an additional 231,827 shares during the period. Cormorant Asset Management LP grew its stake in Praxis Precision Medicines by 3.1% in the first quarter. Cormorant Asset Management LP now owns 1,745,000 shares of the company’s stock valued at $66,083,000 after acquiring an additional 51,781 shares during the period. Vanguard Group Inc. grew its stake in Praxis Precision Medicines by 4.2% in the third quarter. Vanguard Group Inc. now owns 1,267,286 shares of the company’s stock valued at $67,166,000 after acquiring an additional 51,642 shares during the period. Deerfield Management Company L.P. increased its holdings in shares of Praxis Precision Medicines by 22.4% in the third quarter. Deerfield Management Company L.P. now owns 840,851 shares of the company’s stock worth $44,565,000 after acquiring an additional 153,920 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Praxis Precision Medicines by 19.1% in the second quarter. Assenagon Asset Management S.A. now owns 604,298 shares of the company’s stock worth $25,411,000 after acquiring an additional 96,898 shares in the last quarter. 67.84% of the stock is owned by institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.